LY 231617

Product Name: LY 231617
CAS No.: 141545-89-3
Chemical Name: LY 231617
Synonyms: LY 231617;2,6-di-tert-butyl-4-((ethylamino)methyl)phenol hydrochloride;2,6-BIS(1,1-DIMETHYLETHYL)-4-[[(1-ETHYL)AMINO]METHYL]PHENOL, HCL;2,6-bis(1,1-Dimethylethyl)-4-[(ethylamino)methyl]phenol hydrochloride
CBNumber: CB8674928
Molecular Formula: C17H30ClNO
Formula Weight: 299.88
MOL File: 141545-89-3.mol

More

Less

LY 231617 Property

storage temp.: -20°C
solubility: Soluble to 100 mM in DMSO and to 100 mM in ethanol
form: Powder
color: Light yellow to yellow

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

N-Bromosuccinimide Price

Tocris

Product number: 1286
Product name: LY231617
Purity: ≥98%(HPLC)
Packaging: 10
Price: $136
Updated: 2021/12/16

Tocris

Product number: 1286
Product name: LY231617
Purity: ≥98%(HPLC)
Packaging: 50
Price: $515
Updated: 2021/12/16

TRC

Product number: L468950
Product name: LY231617
Packaging: 5mg
Price: $195
Updated: 2021/12/16

Usbiological

Product number: 255717
Product name: LY 231617
Packaging: 10mg
Price: $418
Updated: 2021/12/16

American Custom Chemicals Corporation

Product number: CHM0970184
Product name: 2,6-BIS(1,1-DIMETHYLETHYL)-4-[[(1-ETHYL)AMINO]METHYL]PHENOL, HCL
Purity: 95.00%
Packaging: 5MG
Price: $497.31
Updated: 2021/12/16

More

Less

LY 231617 Chemical Properties,Usage,Production

Uses

LY 231617 is an antioxidant and is able to prevent ischaemia-induced neurodegeneration. LY 231617 is a neuroprotective and an anti-ischaemic agent.

in vivo

LY231617 (50 mg/kg; p.o. 30 minutes before occlusion) reduces global ischemic neuronal injury in rats^[2]. LY231617 (20 mg/kg; i.v. 30 minutes after occlusion) protects hippocampus and striatum from four-vessel occlusion^[2].

Animal Model:	Male Wistar rats four-vessel occlusion^[2]
Dosage:	50 mg/kg
Administration:	Oral gavage; 50 mg/kg 30 minutes before occlusion
Result:	Significantly protected both the hippocampus and striatum from 30 minutes of four-vessel occlusion.

Animal Model:	Male Wistar rats four-vessel occlusion^[2]
Dosage:	20 mg/kg
Administration:	Intravenous injection ; 20 mg/kg 30 minutes after occlusion
Result:	Significantly protected the hippocampus and the striatum when given 30 minutes after the onset of the ischemia at the time of reperfusion.

LY 231617 Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

LY 231617 Suppliers

China 26 Japan 1 United Kingdom 2 United States 5 Global 34

Kanto Chemical Co., Inc.

Tel: --
Fax: --
Email: reag-info@gms.kanto.co.jp
Country: Japan
ProdList: 6756
Advantage: 74

141545-89-3, LY 231617Related Search:

LY 231617 3,5-DI-TERT-BUTYL-4-HYDROXYBENZYLAMINE 3,5-DI-TERT-BUTYL-BENZYLAMINE 4-(Aminomethyl)-2,6-dimethylphenol 1-PIPERAZINEETHANOL, 4-[[3,5-BIS(1,1-DIMETHYLETHYL)-4-HYDROXYPHENYL]METHYL]-A-(4-CHLOROPHENYL)-, HYDROCHLORIDE (1:2)

2,6-bis(1,1-Dimethylethyl)-4-[(ethylamino)methyl]phenol hydrochloride

LY 231617

2,6-BIS(1,1-DIMETHYLETHYL)-4-[[(1-ETHYL)AMINO]METHYL]PHENOL, HCL

2,6-di-tert-butyl-4-((ethylamino)methyl)phenol hydrochloride

141545-89-3

C17H29NOHCl